DexCom, Inc. (DXCM)
Stock Price:
$432.38 USD
-19.41 (-4.30%)
Updated Aug 6, 2020 12:30 PM EDT - Market open
Key Info
| Market Cap |
41.40B |
| Revenue (ttm) |
1.72B |
| Net Income (ttm) |
204.70M |
| Shares Out |
95.74M |
| EPS (ttm) |
2.16 |
| PE Ratio |
200.18 |
| Forward PE |
250.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$432.38 |
| Previous Close |
$451.79 |
| Change ($) |
-19.41 |
| Change (%) |
-4.30% |
| Day's Open |
452.41 |
| Day's Range |
429.56 - 452.89 |
| Day's Volume |
409,497 |
| 52-Week Range |
138.28 - 455.00 |
More Stats
| Market Cap |
41.40B |
| Enterprise Value |
40.64B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
95.74M |
| Float |
95.11M |
| EPS (basic) |
2.23 |
| EPS (diluted) |
2.16 |
| FCF / Share |
2.23 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.50% |
| FCF Yield |
0.50% |
| Payout Ratio |
n/a |
| Shares Short |
3.93M |
| Short Ratio |
3.21 |
| Short % of Float |
4.13% |
| Beta |
0.78 |
| PE Ratio |
200.18 |
| Forward PE |
250.00 |
| P/FCF Ratio |
198.07 |
| PS Ratio |
24.12 |
| PB Ratio |
30.50 |
| Revenue |
1.72B |
| Operating Income |
258.90M |
| Net Income |
204.70M |
| Free Cash Flow |
209.00M |
| Net Cash |
761.20M |
| Net Cash / Share |
7.95 |
| Gross Margin |
54.28% |
| Operating Margin |
15.09% |
| Profit Margin |
11.90% |
| FCF Margin |
12.18% |
| ROA |
6.15% |
| ROE |
20.05% |
| ROIC |
9.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (21)
| Buy |
14 |
| Overweight |
2 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$471.82*
(9.12% upside)
Low
400
Current: $432.38
High
540
Target: 471.82
*Average 12-month price target from 17 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1,476 | 1,032 | 719 | 573 | 402 | 259 | 160 | 99.90 | 76.30 | 48.60 |
| Revenue Growth | 43.08% | 43.58% | 25.33% | 42.61% | 55.09% | 62% | 60.16% | 30.93% | 57% | - |
| Gross Profit | 932 | 664 | 492 | 378 | 278 | 176 | 100 | 46.60 | 35.90 | 18.40 |
| Operating Income | 142 | -186 | -42.50 | -63.90 | -57.10 | -21.50 | -28.90 | -55.70 | -44.80 | -45.30 |
| Net Income | 101 | -127 | -50.20 | -65.60 | -57.60 | -22.40 | -29.80 | -54.50 | -44.70 | -55.20 |
| Shares Outstanding | 91.10 | 88.20 | 86.30 | 83.60 | 79.80 | 75.20 | 71.10 | 68.70 | 65.60 | 56.90 |
| Earnings Per Share | 1.10 | -1.44 | -0.58 | -0.78 | -0.72 | -0.30 | -0.42 | -0.79 | -0.68 | -0.97 |
| Operating Cash Flow | 315 | 123 | 92.00 | 56.20 | 49.00 | 23.60 | 2.40 | -33.10 | -30.10 | -42.70 |
| Capital Expenditures | -180 | -67.10 | -66.00 | -55.70 | -33.30 | -16.20 | -7.90 | -9.50 | -8.00 | -6.90 |
| Free Cash Flow | 135 | 56.10 | 26.00 | 0.50 | 15.70 | 7.40 | -5.50 | -42.60 | -38.10 | -49.60 |
| Cash & Equivalents | 1,533 | 1,386 | 549 | 124 | 115 | 84.60 | 55.60 | 49.70 | 82.90 | 48.83 |
| Total Debt | 1,146 | 1,010 | 328 | - | 2.30 | 4.60 | 6.80 | 7.00 | - | 0.53 |
| Net Cash / Debt | 388 | 375 | 221 | 124 | 113 | 80.00 | 48.80 | 42.70 | 82.90 | 48.30 |
| Assets | 2,395 | 1,916 | 904 | 403 | 292 | 185 | 123 | 106 | 121 | 77.16 |
| Liabilities | 1,512 | 1,253 | 485 | 119 | 70.80 | 44.40 | 38.40 | 29.00 | 16.00 | 16.17 |
| Book Value | 883 | 663 | 419 | 284 | 221 | 140 | 84.10 | 77.00 | 105 | 60.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DexCom, Inc. |
| Country |
United States |
| Employees |
3,900 |
| CEO |
Kevin Ronald Sayer |
Stock Information
| Ticker Symbol |
DXCM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: DXCM |
| IPO Date |
April 14, 2005 |
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.